FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100849006> ?p ?o ?g. }

• W3100849006 endingPage "26" @default.
• W3100849006 startingPage "20" @default.
• W3100849006 abstract "Abstract Background Although the European Medicines Agency and the US Food and Drug Administration have, respectively, approved rivaroxaban for the prevention of recurrent major adverse cardiovascular events in patients with myocardial infarction and stable coronary artery disease, its efficacy and safety is unclear. This meta‐analysis aimed to evaluate the benefit and risk of adding rivaroxaban in coronary artery disease (CAD) patients, focusing on treatment effects stratified by different baseline clinical presentations. Hypothesis There are differences in treatment effects of adding rivaroxaban among CAD patients with different baseline clinical presentations. Methods Medline, EMBASE, and Cochrane Databases were systematically searched from inception to 21 July 2020 for randomized controlled trials (RCTs) comparing rivaroxaban in CAD patients. The primary efficacy endpoint and safety endpoint were assessed by using Mantel–Haenszel pooled risk ratios (RRs) and 95% confidence intervals (CIs). Results Five RCTs that included 43 650 patients were identified. Patients receiving rivaroxaban had a significantly lower risk of the primary efficacy endpoint (RR, 0.86; 95% CI, 0.76–0.97, p = .01) accompanied by increased risk of the primary safety endpoint (RR, 1.83; 95% CI, 1.10–3.05, p = .02). Subgroup analyses showed that in males the risk–benefit appears to be more favorable while in patients ≥65 years, in females, in patients with diabetes, those with mild to moderate impaired renal function, and region of Asia/other seems unfavorable. Conclusion Rivaroxaban may provide an additional choice for secondary prevention in CAD patients. However, careful estimation of the risk of ischemic and bleeding events using patient characteristics are critical to achieving net benefit." @default.
• W3100849006 created "2020-11-23" @default.
• W3100849006 creator A5011795906 @default.
• W3100849006 creator A5017400623 @default.
• W3100849006 creator A5035004931 @default.
• W3100849006 creator A5047949723 @default.
• W3100849006 creator A5059974927 @default.
• W3100849006 creator A5075277705 @default.
• W3100849006 creator A5088394087 @default.
• W3100849006 date "2020-11-21" @default.
• W3100849006 modified "2023-10-18" @default.
• W3100849006 title "Benefit and risk of adding rivaroxaban in patients with coronary artery disease: A systematic review and meta‐analysis" @default.
• W3100849006 cites W1564690174 @default.
• W3100849006 cites W1972901101 @default.
• W3100849006 cites W1973935103 @default.
• W3100849006 cites W1988444147 @default.
• W3100849006 cites W2002189205 @default.
• W3100849006 cites W2025459857 @default.
• W3100849006 cites W2029400346 @default.
• W3100849006 cites W2032105970 @default.
• W3100849006 cites W2072006327 @default.
• W3100849006 cites W2105397247 @default.
• W3100849006 cites W2108064339 @default.
• W3100849006 cites W2117677020 @default.
• W3100849006 cites W2127090290 @default.
• W3100849006 cites W2156496314 @default.
• W3100849006 cites W2156927593 @default.
• W3100849006 cites W2192426125 @default.
• W3100849006 cites W2596358769 @default.
• W3100849006 cites W2767660506 @default.
• W3100849006 cites W2788929631 @default.
• W3100849006 cites W2790711154 @default.
• W3100849006 cites W2806727609 @default.
• W3100849006 cites W2888292644 @default.
• W3100849006 cites W2895112115 @default.
• W3100849006 cites W2987547431 @default.
• W3100849006 cites W3016026237 @default.
• W3100849006 cites W4211143229 @default.
• W3100849006 doi "https://doi.org/10.1002/clc.23514" @default.
• W3100849006 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7803358" @default.
• W3100849006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33219708" @default.
• W3100849006 hasPublicationYear "2020" @default.
• W3100849006 type Work @default.
• W3100849006 sameAs 3100849006 @default.
• W3100849006 citedByCount "3" @default.
• W3100849006 countsByYear W31008490062021 @default.
• W3100849006 countsByYear W31008490062022 @default.
• W3100849006 crossrefType "journal-article" @default.
• W3100849006 hasAuthorship W3100849006A5011795906 @default.
• W3100849006 hasAuthorship W3100849006A5017400623 @default.
• W3100849006 hasAuthorship W3100849006A5035004931 @default.
• W3100849006 hasAuthorship W3100849006A5047949723 @default.
• W3100849006 hasAuthorship W3100849006A5059974927 @default.
• W3100849006 hasAuthorship W3100849006A5075277705 @default.
• W3100849006 hasAuthorship W3100849006A5088394087 @default.
• W3100849006 hasBestOaLocation W31008490061 @default.
• W3100849006 hasConcept C126322002 @default.
• W3100849006 hasConcept C141071460 @default.
• W3100849006 hasConcept C168563851 @default.
• W3100849006 hasConcept C187960798 @default.
• W3100849006 hasConcept C197934379 @default.
• W3100849006 hasConcept C203092338 @default.
• W3100849006 hasConcept C207103383 @default.
• W3100849006 hasConcept C2776301958 @default.
• W3100849006 hasConcept C2778213512 @default.
• W3100849006 hasConcept C2778661090 @default.
• W3100849006 hasConcept C2779161974 @default.
• W3100849006 hasConcept C44249647 @default.
• W3100849006 hasConcept C500558357 @default.
• W3100849006 hasConcept C71924100 @default.
• W3100849006 hasConcept C82789193 @default.
• W3100849006 hasConcept C95190672 @default.
• W3100849006 hasConceptScore W3100849006C126322002 @default.
• W3100849006 hasConceptScore W3100849006C141071460 @default.
• W3100849006 hasConceptScore W3100849006C168563851 @default.
• W3100849006 hasConceptScore W3100849006C187960798 @default.
• W3100849006 hasConceptScore W3100849006C197934379 @default.
• W3100849006 hasConceptScore W3100849006C203092338 @default.
• W3100849006 hasConceptScore W3100849006C207103383 @default.
• W3100849006 hasConceptScore W3100849006C2776301958 @default.
• W3100849006 hasConceptScore W3100849006C2778213512 @default.
• W3100849006 hasConceptScore W3100849006C2778661090 @default.
• W3100849006 hasConceptScore W3100849006C2779161974 @default.
• W3100849006 hasConceptScore W3100849006C44249647 @default.
• W3100849006 hasConceptScore W3100849006C500558357 @default.
• W3100849006 hasConceptScore W3100849006C71924100 @default.
• W3100849006 hasConceptScore W3100849006C82789193 @default.
• W3100849006 hasConceptScore W3100849006C95190672 @default.
• W3100849006 hasFunder F4320321001 @default.
• W3100849006 hasIssue "1" @default.
• W3100849006 hasLocation W31008490061 @default.
• W3100849006 hasLocation W31008490062 @default.
• W3100849006 hasOpenAccess W3100849006 @default.
• W3100849006 hasPrimaryLocation W31008490061 @default.
• W3100849006 hasRelatedWork W1972702180 @default.
• W3100849006 hasRelatedWork W2096190005 @default.
• W3100849006 hasRelatedWork W2114346778 @default.
• W3100849006 hasRelatedWork W2117378160 @default.

• next